Determine the in-vivo mechanism of action of INF-B-1b as it's mechanisms of action are not
completely understood. We propose that high dose exogenous recombinant IFN-B-1b induces
tolerizing effect on DC-dependent T-cell differentiation in patients with MS by inducing the
expression of SOCS3 in DCs.
- Confirmed diagnosis of MS
- Age 18-60 years, inclusive
- Expanded disability status of 0-6.5
- Give written informed consent prior to any testing under this protocol